Finance

Lists
IBAB:EBR
Ion Beam Applications SA
€15,94
+1,40%
(+0,22) 1D
13 Okt., 17:35:00 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for IBAB...
Open
€15,58
High
€15,98
Low
€15,58
Mkt. cap
475,43 m
Avg. vol.
16,63 k
Volume
10,74 k
Dividend
1,10%
Quarterly dividend
€0,04
Ex-dividend date
15 Jun. 2026
P/E ratio
20,02
52-wk high
€17,76
52-wk low
€9,90
EPS
€0,80
Shares outstanding
30,28 m
No. of employees
2 k
Open
€15,58
High
€15,98
Low
€15,58
Mkt. cap
475,43 m
Avg. vol.
16,63 k
Volume
10,74 k
Dividend
1,10%
Quarterly dividend
€0,04
Ex-dividend date
15 Jun. 2026
P/E ratio
20,02
52-wk high
€17,76
52-wk low
€9,90
EPS
€0,80
Shares outstanding
30,28 m
No. of employees
2 k
News stories
From web sources and news partners
Profile
IBA is a medical technology company based in Louvain-la-Neuve. The company was founded in 1986 by Yves Jongen within the Cyclotron Research Center of the University of Louvain and became a university spin-off. It employs about 1500 people in 40 locations. The company developed cyclotrons and integrated proton therapy centers is active in the field of proton therapy, dosimetry, radiopharmacy solutions and industrial sterilisation. IBA installed its first proton therapy equipment for Boston's Massachusetts General Hospital in 2001, and for University of Pennsylvania's Proton Center in 2009. It supplied equipment and services to Proton Partners International which was developing three proton beam therapy centers in the United Kingdom. In 2017, IBA invested €16 million in the construction of a new logistics and production center in Louvain-la-Neuve. Wikipedia
About Ion Beam Applications SA
CEOOlivier Legrain
Employees2,26 k
Founded1986
Headquarters-
SectorMedical device
Websiteiba-worldwide.com
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
157,64 m
157,64 m
161,87 m
161,87 m
Cost of goods sold
102,83 m
102,83 m
107,40 m
107,40 m
Cost of revenue
102,83 m
102,83 m
107,40 m
107,40 m
Research and development expenses
15,48 m
15,48 m
18,20 m
18,20 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
30,94 m
30,94 m
28,22 m
28,22 m
Operating expense
40,94 m
40,94 m
48,03 m
48,03 m
Total operating expenses
143,77 m
143,77 m
155,43 m
155,43 m
Operating income
13,86 m
13,86 m
6,45 m
6,45 m
Other non operating income
-1,29 m
-1,29 m
-
-
EBT including unusual items
8,78 m
8,78 m
6,14 m
6,14 m
EBT excluding unusual items
13,05 m
13,05 m
6,20 m
6,20 m
Income tax expense
1,12 m
1,12 m
1,48 m
1,48 m
Effective tax rate
12,73%
12,73%
24,10%
24,10%
Other operating expenses
-5,83 m
-5,83 m
1,60 m
1,60 m
Net income
7,67 m
7,67 m
4,66 m
4,66 m
Net profit margin
4,86%
4,86%
2,88%
2,88%
Earnings per share
-
-
-
-
Interest and investment income
2,13 m
2,13 m
1,88 m
1,88 m
Interest expense
-
-
-3,18 m
-3,18 m
Net interest expenses
2,13 m
2,13 m
-1,31 m
-1,31 m
Depreciation and amortization charges
-
-
-
-
EBITDA
15,80 m
15,17 m
8,41 m
8,41 m
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme